SC-102 / ConjuStar - LARVOL DELTA

Study of SC-102 in Patients With Advanced Solid Tumors (clinicaltrials.gov) - P1 | N=120 | Recruiting | Sponsor: Tianjin ConjuStar Biologics Co., Ltd. | Not yet recruiting ➔ Recruiting

Enrollment open • Oncology • Solid Tumor

Xinglian Peptide recently completed a RMB 100 million Pre-A+ round of financing, and two products entered the clinical trial stage [Google translation] (vbdata.cn) - "Recently, Tianjin Xinglian Peptide Biotechnology Co., Ltd...announced the completion of a RMB 100 million Pre-A+ round of financing. This round of financing was led by Fosun Pharma's Fujian Capital New Drug Innovation Fund, and followed by Hengqin Venture Capital and Shenzhen Qianhai Liyuan. This round of financing will provide important financial support for Xinglian Peptide's product research and development, to promote clinical trials of core products and new product development, and accelerate the clinical transformation of innovative XDC drugs."

Financing • Oncology